Clinical Trials Directory

Trials / Unknown

UnknownNCT04416425

Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment

Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment: A Serial Follow-Up Study by Computed Tomography-Derived Fractional Flow Reserve

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Zibo Central Hospital · Other Government
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Compelling evidences indicate that lipid-lowering therapy can reduce the high-risk plaque feathers and improve the coronary flow reserve. This study is going to investigate the change of lesion-specific hemodynamic significance as determined by ML(Machine Learning)-based CT-FFR (Computed Tomography-Fractional Flow Reserve)after Evolocumab treatment.

Conditions

Timeline

Start date
2021-07-30
Primary completion
2022-12-31
Completion
2023-02-27
First posted
2020-06-04
Last updated
2021-04-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04416425. Inclusion in this directory is not an endorsement.

Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment (NCT04416425) · Clinical Trials Directory